Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro Recap

Published 10/05/2023, 10:28
Updated 10/05/2023, 10:28
© Reuters.

© Reuters.

Investing.com -- Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday.

Alcon upgraded to Outperform following Q1 beat

Baird upgraded Alcon (NYSE:ALC) to Outperform from Neutral and raised its price target to $90.00 from $75.00 following Q1 earnings.

As always, InvestingPro subscribers got this news first. Start your free 7-day trial to get on board.

Shares jumped more than 7% pre-market today after the company reported its Q1 results, with EPS of $0.70 and revenue of $2.3 billion beating the consensus estimates.

Neogenomics upgraded to Buy, shares jump on Q1 beat

BTIG upgraded NeoGenomics (NASDAQ:NEO) to Buy from Neutral with a price target of $25.00, noting it was impressed by the change in underlying growth at the company since the new management team has taken over.

Shares jumped more than 18% yesterday after the company delivered a strong Q1 beat and raised its full-year guidance.

BTIG said it was positively surprised both by the organic volume (up 7%) and pricing (up 8%) in the core lab services business in Q1, and expects the company to start benefiting from its recent launch of RaDaR MRD in the clinic, as well as Neo Comprehensive, in the clinic in Q2.

2 more upgrades

Enact (NASDAQ:ACT) shares closed more than 2% higher yesterday after BofA Securities upgraded the company to Neutral from Underperform and raised its price target to $27.00 from $25.00. Shares rose more than 2% yesterday.

The company reported its Q1 earnings last week, beating the Street estimates. Earlier this month, the company hiked its dividend by 14% to $0.16.

Piper Sandler upgraded Halozyme Therapeutics (NASDAQ:HALO) to Overweight from Neutral with a price target of $46.00.

Shares surged more than 5% yesterday after the company reported better-than-expected Q1 EPS, while revenues missed expectations.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.